Which has higher valuation & earnings, ALKS or NBTX?

Alkermes has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 5.24 $241.66M $0.38 121.34 Nanobiotix $36.87M 51.62 -$27.11M N/A N/A

Does the media refer more to ALKS or NBTX?

In the previous week, Alkermes had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Alkermes and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.78 beat Alkermes' score of 0.71 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, SYRE or NBTX?

Nanobiotix has higher revenue and earnings than Spyre Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 8,765.35 -$155.20M -$1.95 N/A Nanobiotix $36.87M 51.62 -$27.11M N/A N/A

Is SYRE or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Nanobiotix N/A N/A N/A

Does the media refer more to SYRE or NBTX?

In the previous week, Spyre Therapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Spyre Therapeutics and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.78 beat Spyre Therapeutics' score of 0.47 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RYTM or NBTX?

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rhythm Pharmaceuticals $189.76M 36.91 -$196.54M -$3.11 N/A Nanobiotix $36.87M 51.62 -$27.11M N/A N/A

Does the media favor RYTM or NBTX?

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Rhythm Pharmaceuticals and 3 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 1.29 beat Nanobiotix's score of 0.78 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NBTX or SRRK?

Nanobiotix has higher revenue and earnings than Scholar Rock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 51.62 -$27.11M N/A N/A Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is NBTX or SRRK more profitable?

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Scholar Rock N/A -160.19% -87.18%

Does the media prefer NBTX or SRRK?

In the previous week, Scholar Rock had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Scholar Rock and 3 mentions for Nanobiotix. Scholar Rock's average media sentiment score of 0.82 beat Nanobiotix's score of 0.78 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NBTX or CGON?

Nanobiotix has higher revenue and earnings than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 51.62 -$27.11M N/A N/A CG Oncology $4.04M 1,579.72 -$160.99M -$2.69 N/A

Does the media refer more to NBTX or CGON?

In the previous week, CG Oncology had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Nanobiotix. CG Oncology's average media sentiment score of 1.50 beat Nanobiotix's score of 0.78 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nanobiotix (NBTX) Competitors

$37.60 +0.96 (+2.62%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$36.99 -0.61 (-1.63%)

As of 05:07 AM Eastern

Compare

NBTX vs. ALKS, SYRE, RYTM, SRRK, and CGON

Should you buy Nanobiotix stock or one of its competitors? Nanobiotix's main competitors and comparable companies include Alkermes (ALKS), Spyre Therapeutics (SYRE), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nanobiotix compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Alkermes has a net margin of 3.96% compared to Nanobiotix's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Nanobiotix	N/A	N/A	N/A

Alkermes has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.24	$241.66M	$0.38	121.34
Nanobiotix	$36.87M	51.62	-$27.11M	N/A	N/A

In the previous week, Alkermes had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Alkermes and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.78 beat Alkermes' score of 0.71 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Alkermes shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alkermes has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Alkermes presently has a consensus target price of $54.56, indicating a potential upside of 18.33%. Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 0.71%. Given Alkermes' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alkermes is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Alkermes beats Nanobiotix on 12 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Spyre Therapeutics presently has a consensus target price of $109.69, indicating a potential upside of 23.65%. Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 0.71%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than Spyre Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,765.35	-$155.20M	-$1.95	N/A
Nanobiotix	$36.87M	51.62	-$27.11M	N/A	N/A

Spyre Therapeutics has a beta of 2.99, suggesting that its stock price is 199% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Nanobiotix	N/A	N/A	N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Spyre Therapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Spyre Therapeutics and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.78 beat Spyre Therapeutics' score of 0.47 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spyre Therapeutics beats Nanobiotix on 9 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

38.8% of Nanobiotix shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rhythm Pharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Nanobiotix has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Nanobiotix's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Nanobiotix	N/A	N/A	N/A

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Rhythm Pharmaceuticals and 3 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 1.29 beat Nanobiotix's score of 0.78 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals presently has a consensus target price of $141.12, indicating a potential upside of 38.08%. Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 0.71%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Rhythm Pharmaceuticals is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	36.91	-$196.54M	-$3.11	N/A
Nanobiotix	$36.87M	51.62	-$27.11M	N/A	N/A

Summary

Rhythm Pharmaceuticals beats Nanobiotix on 8 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Scholar Rock?

Nanobiotix (NASDAQ:NBTX) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Nanobiotix has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Scholar Rock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	51.62	-$27.11M	N/A	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nanobiotix currently has a consensus price target of $37.33, suggesting a potential downside of 0.71%. Scholar Rock has a consensus price target of $58.77, suggesting a potential upside of 5.57%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Scholar Rock	N/A	-160.19%	-87.18%

In the previous week, Scholar Rock had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Scholar Rock and 3 mentions for Nanobiotix. Scholar Rock's average media sentiment score of 0.82 beat Nanobiotix's score of 0.78 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scholar Rock beats Nanobiotix on 8 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to CG Oncology?

Nanobiotix (NASDAQ:NBTX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Nanobiotix presently has a consensus target price of $37.33, indicating a potential downside of 0.71%. CG Oncology has a consensus target price of $87.78, indicating a potential upside of 21.91%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, CG Oncology had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Nanobiotix. CG Oncology's average media sentiment score of 1.50 beat Nanobiotix's score of 0.78 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Nanobiotix's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
CG Oncology	-3,602.68%	-25.20%	-23.98%

Nanobiotix has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	51.62	-$27.11M	N/A	N/A
CG Oncology	$4.04M	1,579.72	-$160.99M	-$2.69	N/A

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Nanobiotix and CG Oncology tied by winning 7 of the 14 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.85B	$3.89B	$7.21B	$12.81B
Dividend Yield	N/A	3.63%	2.56%	10.55%
P/E Ratio	N/A	13.60	272.82	25.11
Price / Sales	51.62	1,333.40	620.94	90.53
Price / Cash	N/A	106.61	77.33	51.83
Price / Book	-19.09	15.38	10.43	6.18
Net Income	-$27.11M	-$22.82M	$3.49B	$358.18M
7 Day Performance	-3.09%	-3.97%	-3.16%	-2.51%
1 Month Performance	-2.89%	0.27%	0.02%	-2.73%
1 Year Performance	280.37%	38.62%	17.34%	7.73%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	1.037 of 5 stars	$37.60 +2.6%	$37.33 -0.7%	+293.2%	$1.85B	$36.87M	N/A	100
ALKS Alkermes	2.5846 of 5 stars	$47.00 +0.0%	$54.56 +16.1%	+71.2%	$7.88B	$1.48B	123.69	2,050
SYRE Spyre Therapeutics	2.5423 of 5 stars	$87.77 -1.7%	$109.69 +25.0%	+448.3%	$7.72B	$890K	N/A	73	Analyst Forecast
RYTM Rhythm Pharmaceuticals	3.0429 of 5 stars	$104.67 -1.4%	$141.12 +34.8%	+1.9%	$7.17B	$189.76M	N/A	140	Positive News Gap Down
SRRK Scholar Rock	1.8124 of 5 stars	$56.10 -1.2%	$58.77 +4.8%	+78.2%	$6.83B	N/A	N/A	140	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. ALKS, SYRE, RYTM, SRRK, and CGON

How does Nanobiotix compare to Alkermes?

Summary

How does Nanobiotix compare to Spyre Therapeutics?

Summary

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Summary

How does Nanobiotix compare to Scholar Rock?

Summary

How does Nanobiotix compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. ALKS, SYRE, RYTM, SRRK, and CGON

How does Nanobiotix compare to Alkermes?

Is ALKS or NBTX more profitable?

Which has higher valuation & earnings, ALKS or NBTX?

Does the media refer more to ALKS or NBTX?

Do institutionals and insiders have more ownership in ALKS or NBTX?

Which has more volatility & risk, ALKS or NBTX?

Do analysts prefer ALKS or NBTX?

Summary

How does Nanobiotix compare to Spyre Therapeutics?

Do analysts recommend SYRE or NBTX?

Which has higher valuation and earnings, SYRE or NBTX?

Which has more volatility & risk, SYRE or NBTX?

Is SYRE or NBTX more profitable?

Do institutionals & insiders have more ownership in SYRE or NBTX?

Does the media refer more to SYRE or NBTX?

Summary

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Do insiders & institutionals believe in RYTM or NBTX?

Which has more volatility & risk, RYTM or NBTX?

Is RYTM or NBTX more profitable?

Does the media favor RYTM or NBTX?

Do analysts recommend RYTM or NBTX?

Which has preferable earnings and valuation, RYTM or NBTX?

Summary

How does Nanobiotix compare to Scholar Rock?

Which has more risk & volatility, NBTX or SRRK?

Which has stronger earnings and valuation, NBTX or SRRK?

Do institutionals and insiders hold more shares of NBTX or SRRK?

Do analysts rate NBTX or SRRK?

Is NBTX or SRRK more profitable?

Does the media prefer NBTX or SRRK?

Summary

How does Nanobiotix compare to CG Oncology?

Do analysts recommend NBTX or CGON?

Does the media refer more to NBTX or CGON?

Is NBTX or CGON more profitable?

Which has more risk and volatility, NBTX or CGON?

Which has preferable earnings & valuation, NBTX or CGON?

Do institutionals and insiders believe in NBTX or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools